| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Tilray Medical, a division of Canadian cannabis giant Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Monday a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS).
The study, consisting of patients with an average age of 52 years, examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers.
More precisely, the researchers take a closer look at the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study examined the impact of cannabinoids on health outcomes, with a focus on pain, sleep, and quality of life.
Read Also: Billion-Dollar Cannabis Company Closes Acquisition Of Three US Breweries, What’s Next For Tilray
Under medical cannabis guidance and oversight, the study revealed improvements in pain levels, sleep quality and overall well-being for patients with fibromyalgia.
Additionally, a significant decrease in the need for other medications was observed, indicating that cannabinoids could be a promising and cost-effective treatment choice for this group of patients.
Moreover, the findings offer important insights for both the medical and scientific communities related to the potential of cannabinoids to manage chronic pain and elevate the quality of life for fibromyalgia sufferers.
"The findings of this study are encouraging and provide hope for fibromyalgia patients who are seeking effective treatments," pills José Tempero, Tilray's medical director.
“Tilray's involvement in this study underscores our unwavering commitment to advancing medical research and unlocking the full therapeutic potential of medical cannabis," added Denise Faltischek, chief strategy officer and head of international at Tilray Brands. "The TOMAS study and its positive outcomes for patients with fibromyalgia, highlights the potential of cannabinoids as a safe and effective treatment option for patients with chronic pain and associated symptoms."
Read Also:
Tilray’s shares trade 2.78% higher at $1.665 per share during the pre-market session on Monday morning.
